The World Anti-doping Authority (WADA) wants pharmaceutical manufacturers to identify drug candidates in their pipelines that could be used to cheat in sport.
in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes on the pharmaceutical careers ladder, including news from ABPI, Cubist and Oxford Pharmascience.
Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
Outsourcing Pharma presents its weekly round-up of the latest new faces and appointments in the pharmaceutical industry, including news from Patheon, CTI and PRECOS.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
Outsourcing-pharma.com presents a round up the latest developments in the contract manufacturing sector – with news from Cambrex, Florida Biologix, SCM Pharma, Recipharm and OctoPlus.
Outsourcing-Pharma presents a round-up of the latest contract manufacturing headlines in the industry, including news from Nanohale, Fleming and Trophogen.
The US Food and Drug Administration (FDA) will soon start asking drugmakers to play a greater role in guideline development. Before that process begins in-Pharmatechnologist.com takes a look at the documents published by the agency in 2011.
Outsourcing-Pharma presents its weekly round-up of the latest movers and shakers in the pharmaceutical industry, including news from Inviragen, Auxilium, and Icon Biosciences.
The contract research sector has grown markedly over the last decade, with more drugs being examined in more trials by more researchers according to a new Association of Clinical Research Organisations (ACRO) survey.
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
Alkermes has celebrated the launch of its new Irish drug delivery and formulation business by winning a new multimillion dollar manufacturing contract with a ‘top 10 pharma.’
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
Irish pharma giant Elan is investing $20m (€14m) in US drug developer Proteostasis Therapeutics to speed the research and development of disease modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders.
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at A10, Crystal Pharmatech and Algos.
Almac Pharma Services has expanded its cold storage capacity for biopharmaceuticals, continuing the contract manufacturing organisation’s (CMO) busy expansion programme.
Shanghai-based CRO, ChemPartner, a subsidiary of Chinese biotech outsourcing company, ShangPharma, has signed a research services agreement with China-based oncology specialists, Shenogen Pharma, to develop therapeutic antibodies for use in the treatment...
Merck plans to cash in on the biogenerics industry after forming a partnership with Parexel to develop copies of biologic drugs within its Merck BioVentures division.
Enlight Biosciences, a Boston, US-based drug discovery and development technologies company, has formed the new company, Entrega, which focuses on oral drug delivery techniques.
Drug developers are “aggressively changing” research and development (R&D) methods in the pursuit of the next blockbuster, according to the Tufts Centre for the Study of Drug Development (Tufts CSDD).
Quintiles and London Genetics will offer pharmacogenetics solutions to the biopharma industry after collaborating to help advance personalised medicine.